Chemotargets’ proprietary ProSurfScan AI-driven de novo drug design platform uses novel structure-based methods of agnostically scanning the entire surface of a protein structure to perform a virtual fragment-based screening of all possible drug binding cavities.
Move Quickly – In the Right Direction
We serve the needs of our global partners by leveraging our expertise across multiple therapeutic areas and in a variety of applications including:
What we look for?
We are interested in developing win-win collaborative relationships with world class academia, government institutions and centers dedicated to basic research. Our focal point is innovation.
We seek to participate in projects based on scientific excellence and a passion for creating new and differentiated approaches to improve drug discovery technologies and quality knowledge resources. The goal is to develop better and safer therapeutic agents by having a full scope perspective of diseases and the interactions between them.
Our Collaboration Model
Our model is based on sharing excellent scientific projects, whether these are driven by drug discovery or are focused on complementing technologies and knowledge platforms. Chemotargets SL gives its collaborators the opportunity to benefit from its state-of-the-art in silico tools and prediction modeling programs, and in turn our collaborators bring their expertise and knowledge resources in specific therapeutic areas.
Chemotargets also maintains agreements with the full complements of critical drug discovery and development service providers from chemical synthesis to PhaseI clinical trials.
Working with Goverment Organizations
Chemotargets SL collaborates with multiple government-backed organizations, academic research centers and EU funded research projects. Contact us for more information about our Collaboration opportunities.